Role of thiols, pH and cathepsin D in the lysosomal catabolism of serum albumin.
Attempts were made to assess the role of thiols and to determine the cathepsins involved in the degradation of serum albumin in mouse liver and kidney lysosomes. Unlike cysteine or beta-mercaptoethanol, reduced glutathione (GSH) did not stimulate the degradation of formaldehyde-treated albumin in liver lysosomes, suggesting that the tripeptide did not penetrate the membrane. However, GSH was a much more effective stimulant of proteolysis in kidney lysosomes than was cysteine at low concentrations, and the effect was saturable at 1-2 mM concentrations. Thiols did not stimulate proteolysis in lysosomes when the disulphide bonds of albumin were reduced and alkylated, suggesting that the stimulatory effects were solely due to disulphide-bond reduction in protein substrates. Results obtained with thiols and iodoacetamide suggested that albumins denatured by disulphide-bond reduction and alkylation, disulphide-bond reduction without alkylation, or by treatment with 8 M-urea, were all degraded primarily by cathepsin D in lysosomes, but formaldehyde-denatured albumin was attacked by thiol proteinases. These findings correlated well with studies on the degradation of these proteins by rat liver lysosome (tritosome) extracts. Studies with the proteinase inhibitors leupeptin and pepstatin and the stimulatory effects of thiols in these extracts suggested that formaldehyde-denatured albumin was degraded primarily by the thiol proteinases, but that native albumin or albumins denatured by disulphide-bond reduction or by treatment with 8 M-urea were attacked by cathepsin D. Denaturation of serum albumin by any of the methods used caused a shift in the pH optimum of albumin catabolism by tritosome extracts or by purified cathepsin D from approx. 3-4 to 5-6. These results were discussed in terms of a possible mechanism for the catabolic aspect of serum albumin turnover.
D000818:Animals; D002402:Cathepsin D; D002403:Cathepsins / Q000378:metabolism*; D003545:Cysteine / Q000494:pharmacology; D005978:Glutathione / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007460:Iodoacetamide / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism; D007976:Leupeptins / Q000494:pharmacology; D008099:Liver / Q000378:metabolism; D008247:Lysosomes / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D010436:Pepstatins / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012710:Serum Albumin, Bovine / Q000378:metabolism*; D013438:Sulfhydryl Compounds / Q000494:pharmacology*
D007976:Leupeptins; D010436:Pepstatins; D013438:Sulfhydryl Compounds; C014195:Streptomyces pepsin inhibitor; D012710:Serum Albumin, Bovine; D002403:Cathepsins; D002402:Cathepsin D; D005978:Glutathione; C032854:leupeptin; D003545:Cysteine; C031375:pepstatin; D007460:Iodoacetamide